CSPC Megalith Biopharmaceutical

Privately held: no public share price

Assets

(1 total)
1Total Assets
0Approved
1Phase 3 / Filed
0Phase 1–2 / Early
2Diseases
Quick filter:
Showing 1 of 1 assets
Target & Modality
Phase 3
Nectin-4Antibody–drug conjugate
Cervical CancerBladder / Urothelial Cancer
Urothelial Carcinoma

Upcoming events

(6 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (3)
January 2027 (1)
Sutantatug envedotinPhase 1/2Solid Tumor, Adult
Est. primary completion 2027-01-16 · NCT06265727 · CT.gov ↗
What to watch
December 2027 (2)
Sutantatug envedotinPhase 3Oropharyngeal Carcinoma (OPC)
Est. primary completion 2027-12 · NCT07768189 · CT.gov ↗
What to watch
Sutantatug envedotinPhase 2Head and Neck Squamous Cell Carcinoma
Est. primary completion 2027-12-30 · NCT06989671 · CT.gov ↗
What to watch
2028 (2)
January 2028 (1)
Sutantatug envedotinPhase 3Cervical Cancer
Est. primary completion 2028-01-01 · NCT07230626 · CT.gov ↗
What to watch
June 2028 (1)
Sutantatug envedotinPhase 2Advanced Urothelial Carcinoma
Est. primary completion 2028-06-01 · NCT07374549 · CT.gov ↗
What to watch
2029 (1)
June 2029 (1)
Sutantatug envedotinPhase 3Urothelial Carcinoma
Est. primary completion 2029-06-01 · NCT07526792 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

No financial reports recorded.